Parkinson's Disease Dementia: Etiology, Mechanisms, Diagnosis, Management and Future Directions

A Abyad

Correspondence:
A. Abyad, MD, MPH, MBA, DBA, AGSF
Consultant, Internal Medicine and Geriatric, Dar Al Shifa Hospital, Kuwait
Chairman, Middle-East Academy for Medicine of Aging.
President, Middle East & North Africa Association on Aging & Alzheimer's
Coordinator, Middle-East Primary Care Research Network
Coordinator, Middle-East Network on Aging
Email: aabyad@cyberia.net.lb

Received: May 2026. Accepted: May 2026; Published: June 2026.
Citation: Abyad A. Parkinson's Disease Dementia: Etiology, Mechanisms, Diagnosis, Management and Future Directions. World Family Medicine. June 2026; 24(4): 30- 45 DOI: 10.5742/MEWFM.2026.241781

Abstract

Parkinson's disease dementia (PDD) is a common, disabling, and prognostically important neurocognitive syndrome arising in the context of established Parkinson's disease (PD). It represents one of the major late-stage manifestations of synucleinopathy and reflects the convergence of cortical Lewy body pathology, cholinergic degeneration, dopaminergic network dysfunction, Alzheimer-type co-pathology, neuroinflammation, vascular injury, and age-related vulnerability. Clinically, PDD is characterized by progressive impairment in attention, executive function, visuospatial processing, memory retrieval, and behavioural regulation, typically accompanied by neuropsychiatric symptoms such as visual hallucinations, apathy, depression, anxiety, delusions, REM sleep behaviour disorder, and fluctuating cognition. The diagnostic distinction between PDD and dementia with Lewy bodies remains anchored in the one-year rule, although biological and clinicopathological evidence increasingly supports their conceptualization as overlapping Lewy body dementias. Diagnosis remains primarily clinical, supported by neuropsychological testing, structural and functional imaging, exclusion of reversible contributors, and emerging biomarkers including α-synuclein seed amplification assays, amyloid and tau biomarkers, and neurodegeneration markers. Rivastigmine remains the best-supported symptomatic pharmacologic therapy, while management requires systematic rationalization of dopaminergic and anticholinergic medication, treatment of neuropsychiatric complications, sleep optimization, rehabilitation, caregiver support, and advanced-care planning. Disease-modifying therapies remain investigational, but future directions include biological staging, precision phenotyping, synuclein-targeted immunotherapy, lysosomal enhancement, neuroinflammation modulation, digital biomarkers, and integrated trials across the Lewy body disease spectrum.

Keywords: Parkinson's disease dementia; Lewy body dementia; α-synuclein; cognitive impairment; rivastigmine; dementia with Lewy bodies; neurodegeneration; synucleinopathy

Overview

Parkinson's disease dementia (PDD) is a progressive major neurocognitive disorder that develops in patients with established Parkinson's disease (PD). It is clinically defined by cognitive decline severe enough to impair activities of daily living and occurring in the setting of previously diagnosed idiopathic PD. The central diagnostic premise is temporal: motor Parkinsonism precedes dementia by more than one year. When dementia precedes or emerges within one year of Parkinsonism, the syndrome is conventionally classified as dementia with Lewy bodies (DLB), although both disorders share α-synuclein pathology and are increasingly viewed as related clinical expressions within a Lewy body disease continuum (Emre et al., 2007; McKeith et al., 2017; Aarsland et al., 2021).

PDD is not merely an extension of motor PD. It represents widespread failure of distributed neural systems, particularly frontostriatal, limbic, cholinergic, attentional, and posterior cortical networks. The cognitive profile differs from typical Alzheimer's disease in that early impairments often involve attention, executive function, processing speed, visuospatial ability, and retrieval-based memory rather than isolated amnestic encoding failure (Emre et al., 2007; Litvan et al., 2012; Aarsland et al., 2021). Nevertheless, Alzheimer-type amyloid and tau pathology frequently coexist and influence phenotype, progression, and prognosis (Irwin et al., 2013; Compta et al., 2011; Halliday et al., 2014).

The clinical importance of PDD is substantial. Cognitive impairment in PD predicts loss of independence, medication complexity, psychosis, falls, institutionalization, caregiver burden, and mortality (Hely et al., 2008; Lawson et al., 2016; Aarsland et al., 2021). PDD also complicates treatment of motor symptoms because dopaminergic escalation can aggravate hallucinations, impulse-control symptoms, confusion, and orthostatic hypotension, while reduction of dopaminergic therapy may worsen mobility and quality of life. Thus, clinical reasoning in PDD requires balancing cognition, psychosis, sleep, autonomic function, mobility, swallowing, falls risk, caregiver capacity, and patient preferences.

From a neuropathological standpoint, PDD is usually associated with cortical and limbic Lewy body-type α-synuclein pathology, frequently accompanied by degeneration of cholinergic nuclei, noradrenergic and serotonergic systems, dopaminergic mesocortical pathways, and variable amyloid-β and tau co-pathology (Braak et al., 2003; Halliday et al., 2014; Irwin et al., 2013). The heterogeneity of PDD arises from differential involvement of these systems. A patient with severe cholinergic and posterior cortical involvement may present with hallucinations, attentional fluctuation, and visuospatial impairment, whereas another with prominent frontostriatal dysfunction may show dysexecutive slowing, apathy, and impaired planning.

Etiology

The etiology of PDD is multifactorial and cannot be attributed to a single lesion, neurotransmitter deficit, or proteinopathy. Rather, PDD emerges when neurodegenerative burden crosses a threshold sufficient to impair large-scale cognitive networks. The dominant etiological substrate is Lewy body disease, but dementia risk is shaped by age, disease duration, genetic susceptibility, motor phenotype, neuropsychiatric manifestations, sleep disorders, autonomic dysfunction, vascular injury, systemic illness, and medication exposure.

The primary pathological process is aggregation of misfolded α-synuclein into Lewy bodies and Lewy neurites. In PD, α-synuclein pathology classically involves the substantia nigra and other brainstem nuclei, but progression to limbic and neocortical regions is strongly associated with dementia (Braak et al., 2003; Dickson, 2018). Cortical Lewy body pathology is particularly relevant when it affects temporal, parietal, cingulate, and frontal association cortices. However, the relationship between Lewy body counts and cognition is imperfect, suggesting that synaptic dysfunction, soluble α-synuclein species, network disconnection, and co-pathologies may be as important as visible inclusions (Kramer & Schulz-Schaeffer, 2007; Halliday et al., 2014).

Cholinergic degeneration is another central etiological contributor. The nucleus basalis of Meynert, pedunculopontine nucleus, and other cholinergic structures are affected in PD and PDD. Cholinergic dysfunction correlates with attentional deficits, visual hallucinations, fluctuations, gait impairment, and falls (Bohnen & Albin, 2011; Bohnen et al., 2015). The therapeutic benefit of cholinesterase inhibitors, particularly rivastigmine, supports the clinical relevance of cholinergic loss (Emre et al., 2004).

Alzheimer-type pathology contributes variably to PDD. Amyloid-β plaques and tau neurofibrillary tangles are more frequent in cognitively impaired PD than in cognitively normal PD and may accelerate cognitive decline (Compta et al., 2011; Irwin et al., 2013). The presence of mixed Lewy and Alzheimer pathology may shift the phenotype toward more prominent memory impairment and faster progression.

Medication effects are not usually the primary etiology of PDD, but they can unmask or exacerbate cognitive impairment. Anticholinergics, dopamine agonists, amantadine, benzodiazepines, opioids, sedative hypnotics, and polypharmacy may contribute to delirium, hallucinations, orthostasis, and attentional impairment. The clinician must therefore distinguish progressive dementia from medication-induced encephalopathy or delirium, particularly when symptoms evolve abruptly.

Epidemiology

Cognitive impairment is common across the PD disease course. Mild cognitive impairment in PD may occur early, including near diagnosis, whereas dementia typically increases with age and disease duration (Aarsland et al., 2021). Longitudinal studies indicate that a substantial proportion of patients with PD develop dementia over time, with cumulative risk rising markedly after 10–20 years of disease (Hely et al., 2008; Buter et al., 2008; Aarsland et al., 2021).

The prevalence of PDD varies by diagnostic criteria, population age, disease duration, ascertainment method, and survival bias. Clinic-based cohorts tend to over-represent advanced disease, whereas community-based studies may capture broader severity. Older age at PD onset, greater motor severity, postural instability-gait disorder phenotype, hallucinations, REM sleep behaviour disorder, autonomic dysfunction, depression, and baseline mild cognitive impairment consistently predict dementia (Aarsland et al., 2003; Williams-Gray et al., 2009; Lawson et al., 2016).

The epidemiology of PDD is also shaped by survival. Patients with tremor-dominant PD and younger onset may live for many years before dementia, while patients with older-onset akinetic-rigid or postural instability phenotypes may progress more quickly. Male sex has often been associated with higher PD incidence and may influence dementia risk indirectly through phenotype, comorbidity, and survival, although sex-specific risk estimates vary across cohorts.

Table 1. Epidemiologic and clinical risk factors for PDD

Risk factor	Clinical implication	Mechanistic interpretation
Older age	Strongest demographic predictor	Reduced cognitive reserve, higher mixed pathology burden
Longer PD duration	Dementia risk increases over time	Progressive cortical and limbic spread of synucleinopathy
Older age at PD onset	Higher early dementia risk	Greater baseline vulnerability and co-pathology
Postural instability-gait disorder phenotype	Higher dementia and falls risk	Non-dopaminergic network involvement
Visual hallucinations	Predictor and marker of Lewy body dementia phenotype	Cholinergic dysfunction and posterior cortical involvement
REM sleep behaviour disorder	Associated with diffuse synucleinopathy	Brainstem-limbic network involvement
Orthostatic hypotension/autonomic dysfunction	Associated with cognitive decline	Diffuse α-synuclein burden and vascular vulnerability
PD-MCI	Major prodromal state	Early network-level cognitive involvement
GBA mutation	Increased risk and faster decline	Lysosomal dysfunction and α-synuclein accumulation
Alzheimer co-pathology	Faster decline and memory impairment	Amyloid-tau-synuclein interaction

Genetic Factors

PDD is usually sporadic, but genetic factors influence susceptibility, age at onset, phenotype, and rate of cognitive decline. The strongest and most clinically relevant genetic association is with glucocerebrosidase gene variants. GBA encodes the lysosomal enzyme glucocerebrosidase, and heterozygous pathogenic variants increase risk for PD and are associated with earlier onset, more rapid progression, autonomic dysfunction, hallucinations, and dementia (Sidransky et al., 2009; Gan-Or et al., 2015; Liu et al., 2016). The mechanistic link is biologically plausible: impaired lysosomal function may reduce α-synuclein clearance, while α-synuclein accumulation may further impair glucocerebrosidase trafficking, creating a pathogenic feedback loop.

SNCA mutations and multiplications are associated with autosomal dominant PD and may produce prominent cognitive impairment, psychiatric symptoms, and dementia, especially with gene multiplications that increase α-synuclein dosage (Singleton et al., 2003; Fuchs et al., 2007). These families illustrate the principle that α-synuclein burden is sufficient to drive a diffuse Lewy body phenotype.

MAPT haplotypes have been associated with cognitive outcomes in PD. Tau biology may influence network vulnerability, especially where Alzheimer-type pathology coexists. APOE ε4 is associated with Alzheimer's disease risk and may also influence cognitive decline in PD, likely through amyloid and tau pathways rather than synuclein-specific mechanisms (Irwin et al., 2013; Tsuang et al., 2013).

LRRK2-associated PD is heterogeneous. Some LRRK2 patients resemble idiopathic PD, while others show less cognitive impairment and less Lewy body pathology, depending on mutation, ancestry, and pathological substrate. This variability emphasizes that clinical PD is etiologically heterogeneous and that dementia risk is not uniform across genetic forms.

Table 2. Genetic contributors to cognitive impairment and PDD

Gene/locus	Biological pathway	PDD relevance	Clinical interpretation
GBA	Lysosomal function	Strong association with cognitive decline and dementia	High-risk genotype; consider closer cognitive surveillance
SNCA	α-synuclein production/aggregation	Multiplications associated with dementia and psychiatric features	Supports dose-dependent synuclein toxicity
MAPT	Tau biology	Modifies cognitive phenotype and risk	Suggests tau-synuclein interaction
APOE	Lipid transport, amyloid risk	ε4 may increase cognitive decline risk	Often indicates mixed Alzheimer-Lewy vulnerability
LRRK2	Kinase signalling, vesicle trafficking	Variable dementia risk	Mutation-specific and pathology-dependent
PRKN/PINK1/DJ-1	Mitochondrial quality control	Often young-onset; dementia less typical early	Cognitive risk depends on duration and phenotype

Pathophysiology

The pathophysiology of PDD is best understood as a multi-level process involving protein aggregation, synaptic failure, neurotransmitter depletion, circuit disruption, neuroinflammation, mitochondrial dysfunction, lysosomal impairment, and co-pathology.

1 α-Synuclein aggregation and propagation
α-Synuclein is a presynaptic protein involved in vesicular trafficking and synaptic function. In disease states, misfolded α-synuclein aggregates into oligomers, fibrils, Lewy neurites, and Lewy bodies. The distribution of Lewy pathology correlates broadly with clinical stage. Brainstem-predominant pathology produces motor and autonomic features; limbic and neocortical involvement is more closely associated with hallucinations, fluctuations, and dementia (Braak et al., 2003; Dickson, 2018).

The prion-like propagation hypothesis proposes that pathological α-synuclein spreads through connected neural systems. Although this model remains debated, it explains the stereotyped involvement of olfactory, autonomic, brainstem, limbic, and cortical regions in many patients. The cognitive phenotype depends not simply on the presence of α-synuclein but on where it accumulates, which neurons are vulnerable, and how it interacts with aging and co-pathologies.

2 Cholinergic dysfunction
Cholinergic loss is one of the most important neurochemical correlates of PDD. Degeneration of the Nucleus Basalis of Meynert (NBM) reduces cortical acetylcholine, compromising attention, arousal, visual processing, and memory retrieval. Cholinergic deficits may be more severe in PDD than in Alzheimer's disease in certain cortical regions, which helps explain the responsiveness of some patients to cholinesterase inhibitors (Bohnen & Albin, 2011; Emre et al., 2004).
Clinically, cholinergic dysfunction helps unify several PDD features: fluctuating cognition, visual hallucinations, attentional lapses, falls, gait instability, and sleep-wake dysregulation. This also explains why anticholinergic drugs can be disproportionately harmful in PD patients at risk for dementia.

3 Dopaminergic and frontostriatal dysfunction
The dopaminergic model of PD cognition emphasizes frontostriatal loops. Dopamine depletion in dorsal striatum and mesocortical pathways impairs working memory, cognitive flexibility, set-shifting, and planning. Early PD-MCI often manifests as dysexecutive slowing related to frontostriatal dysfunction. However, dementia usually requires additional posterior cortical, cholinergic, limbic, or Alzheimer-type pathology. This distinction is clinically important: dopaminergic optimization may improve some executive functions in selected patients but can worsen hallucinations, impulsivity, and confusion in PDD.

4 Posterior cortical involvement
Visuospatial dysfunction is a major predictor of dementia in PD. Impairment in pentagon copying, clock drawing, visual discrimination, and spatial orientation often reflects posterior cortical involvement. Occipital and parietal hypometabolism on FDG-PET, posterior cortical atrophy, and cholinergic denervation have been associated with Lewy body dementia phenotypes (McKeith et al., 2017; Aarsland et al., 2021).

5 Alzheimer-type co-pathology
Amyloid-β and tau co-pathology are common in older patients with Lewy body disease and may accelerate cognitive decline. Patients with both Lewy and Alzheimer pathology often show more severe memory impairment, faster progression, and reduced survival compared with patients with relatively pure synucleinopathy (Compta et al., 2011; Irwin et al., 2013). This co-pathology complicates biomarker interpretation and may eventually justify biologically stratified treatment trials.

6 Neuroinflammation, mitochondrial dysfunction, and lysosomal impairment
Microglial activation, oxidative stress, mitochondrial dysfunction, and impaired autophagy-lysosomal pathways contribute to neuronal injury in PD and PDD. GBA-associated disease illustrates the importance of lysosomal biology. Mitochondrial impairment may contribute to neuronal vulnerability in substantia nigra and cortical networks. Neuroinflammation may amplify synaptic dysfunction and protein aggregation, although it remains uncertain whether inflammatory changes are primary drivers or secondary responses.

Differential Diagnosis

The differential diagnosis of cognitive decline in PD is broad. The most important distinction is between PDD and DLB. The one-year rule remains the practical clinical convention: dementia developing after more than one year of established PD supports PDD; dementia preceding or occurring within one year of Parkinsonism supports DLB (McKeith et al., 2017). This rule is imperfect biologically but useful clinically and in research.

Alzheimer's disease should be considered when early memory encoding failure, prominent hippocampal atrophy, aphasia, or biomarker evidence of amyloid and tau pathology is present. Vascular cognitive impairment is suggested by stepwise decline, focal neurological signs, extensive white matter disease, lacunes, strategic infarcts, or vascular risk burden. Normal pressure hydrocephalus may mimic gait disorder and cognitive impairment but typically presents with magnetic gait, urinary symptoms, ventriculomegaly, and a different motor pattern.

Medication-induced cognitive impairment is common and must be actively excluded. Anticholinergics, dopamine agonists, amantadine, sedatives, opioids, and polypharmacy can produce confusion, hallucinations, and attentional impairment. Delirium must be considered when cognitive change is acute or fluctuates dramatically over hours to days.

Depression may produce cognitive symptoms, but true PDD often shows objective visuospatial and executive deficits, hallucinations, functional decline, and progressive course. Sleep disorders, hypothyroidism, vitamin B12 deficiency, infection, dehydration, renal or hepatic dysfunction, and sensory impairment may worsen cognition and should be addressed.

Table 4. Differential diagnosis of dementia in a patient with Parkinsonism

Diagnosis	Key distinguishing features	Clinical reasoning point
PDD	Dementia develops after established PD, usually >1 year after motor onset	Diagnosis requires cognitive functional decline beyond motor disability
DLB	Dementia before or within 1 year of Parkinsonism; early hallucinations/fluctuations	Biological overlap with PDD; temporal rule remains conventional
Alzheimer's disease	Early amnestic encoding deficit, hippocampal atrophy, amyloid/tau biomarkers	Common co-pathology in PDD
Vascular cognitive impairment	Stepwise decline, focal signs, infarcts, severe small vessel disease	May coexist and lower cognitive reserve
Drug-induced cognitive impairment	Temporal relationship to medication change	Review anticholinergics, dopamine agonists, amantadine, sedatives
Delirium	Acute onset, altered arousal, medical trigger	Must be excluded before diagnosing progression
Normal pressure hydrocephalus	Ventriculomegaly, gait apraxia, urinary symptoms	Parkinsonism can coexist
Frontotemporal dementia	Early disinhibition, compulsions, aphasia	Parkinsonism may occur in atypical syndromes
Progressive supranuclear palsy	Early falls, vertical gaze palsy, axial rigidity	Cognitive syndrome often frontal
Multiple system atrophy	Severe autonomic failure, cerebellar signs	Dementia less prominent early

Diagnostic Approach

Diagnosis of PDD is clinical, supported by structured cognitive assessment and exclusion of alternative causes. The Movement Disorder Society criteria define probable PDD by established PD, dementia syndrome with impairment in more than one cognitive domain, decline from premorbid level, functional impairment, and absence of features suggesting another primary cause (Emre et al., 2007; Dubois et al., 2007).

Table 5. Diagnostic criteria for Parkinson's disease dementia

Domain	Requirement
Established PD	Diagnosis of idiopathic PD precedes dementia
Dementia syndrome	Cognitive decline from previous level
Cognitive domains	Impairment in more than one domain, commonly attention, executive function, visuospatial ability, and memory
Functional impairment	Cognitive deficits impair daily living independent of motor symptoms
Associated features	Apathy, hallucinations, delusions, depression, anxiety, excessive daytime sleepiness, fluctuations
Exclusion	Delirium, major depression alone, medication toxicity, vascular event, metabolic disease, other dementia syndrome
Temporal distinction	Dementia occurs after at least one year of established Parkinsonism

1 Clinical history

The clinician should establish the chronology of motor symptoms, cognitive decline, hallucinations, fluctuations, sleep disturbance, medication changes, and functional loss. Collateral history is essential because insight is often impaired. The history should identify whether deficits interfere with instrumental activities of daily living such as medication administration, finances, shopping, cooking, driving, communication, and appointment management.

2 Cognitive screening

The Montreal Cognitive Assessment is generally more sensitive than the Mini-Mental State Examination for PD-related executive and visuospatial deficits. However, screening tests are insufficient for complex cases. Neuropsychological testing should assess attention, processing speed, executive function, visuospatial ability, memory, language, mood, and performance validity. In advanced PD, motor slowing, tremor, dysarthria, fatigue, and visual impairment may confound testing; therefore, interpretation should be individualized.

3 Functional assessment

Functional impairment should be attributed carefully. Cognitive impairment may be masked by caregiver compensation. Conversely, motor disability may mimic cognitive dependence. Structured informant scales, medication management review, financial capacity assessment, and occupational therapy evaluation can help determine whether cognition independently affects daily living.

4 Clinical algorithm

Step	Action	Clinical purpose
1	Confirm idiopathic PD and chronology	Distinguish PDD from DLB and atypical Parkinsonism
2	Obtain collateral cognitive and functional history	Identify decline and real-world impairment
3	Review medications and recent medical events	Exclude reversible cognitive worsening
4	Screen cognition with MoCA or comparable instrument	Establish objective impairment
5	Perform neuropsychological testing when diagnosis uncertain	Define domains and severity
6	Screen mood, psychosis, sleep, autonomic symptoms	Identify treatable contributors
7	Order laboratory tests and structural imaging	Exclude metabolic, vascular, mass, hydrocephalus causes
8	Consider biomarkers when phenotype is atypical or trials are considered	Detect synuclein, amyloid, tau, or neurodegeneration signatures
9	Apply PDD criteria	Assign probable or possible diagnosis
10	Stage severity and create management plan	Align treatment with goals and safety

Laboratory and Imaging Studies

Laboratory tests do not diagnose PDD but are necessary to identify reversible or contributory causes. A reasonable baseline evaluation includes complete blood count, electrolytes, renal and liver function, thyroid-stimulating hormone, vitamin B12, folate when indicated, glucose or HbA1c, inflammatory or infectious tests when clinically suspected, and medication/toxicology review when relevant.

Structural MRI is recommended in most patients with new or worsening cognitive impairment. MRI may show generalized atrophy, posterior cortical atrophy, medial temporal atrophy if Alzheimer co-pathology is present, white matter disease, lacunes, infarcts, microbleeds, hydrocephalus, mass lesions, or subdural collections. Imaging is particularly important when decline is rapid, focal signs are present, gait changes are disproportionate, or vascular disease is suspected.

FDG-PET can show posterior cortical hypometabolism, including occipital and parietotemporal regions, in Lewy body dementia. Dopamine transporter imaging supports presynaptic dopaminergic degeneration but does not distinguish PDD from DLB and is less useful when PD is already established. Cardiac MIBG scintigraphy may support Lewy body disease in some settings but is affected by cardiac disease and medications.

Amyloid and tau PET or CSF biomarkers may be useful when Alzheimer co-pathology is suspected, when phenotype is atypically amnestic, or when disease-modifying Alzheimer therapies are being considered. α-Synuclein seed amplification assays are among the most important emerging biomarkers because they detect misfolded α-synuclein seeding activity and may enable biological classification of synucleinopathies. Their role in routine PDD diagnosis is still evolving, but they are increasingly important for research stratification and future disease-modifying trials.

Table 6. Laboratory and imaging studies in suspected PDD

Investigation	Role	Interpretation
CBC, CMP	Detect anaemia, infection clues, renal/hepatic dysfunction	Abnormalities may cause delirium or worsen cognition
TSH, vitamin B12	Detect reversible cognitive contributors	Treat deficiencies but do not assume they fully explain syndrome
MRI brain	Exclude structural lesions and assess vascular/atrophy burden	Mixed vascular or Alzheimer pathology may be suggested
FDG-PET	Characterize metabolic pattern	Posterior cortical hypometabolism supports Lewy body dementia phenotype
DAT-SPECT	Demonstrate dopaminergic deficit	Useful if Parkinsonism diagnosis uncertain
Amyloid/tau biomarkers	Detect Alzheimer co-pathology	Helps explain amnestic phenotype or rapid decline
α-Synuclein SAA	Detect synuclein seeding activity	Emerging biological marker; strongest research role currently
Polysomnography	Confirm REM sleep behaviour disorder or sleep apnea	Treatable sleep disorders affect cognition and safety

Histopathology

Histopathology is not required for clinical diagnosis but remains the reference standard for understanding disease mechanisms. The defining pathological feature is Lewy body-type α-synuclein pathology involving brainstem, limbic, and neocortical regions. Lewy bodies are eosinophilic intraneuronal inclusions containing α-synuclein, ubiquitin, neurofilament proteins, and other components. Lewy neurites represent abnormal α-synuclein accumulation in neuronal processes and may be more closely related to synaptic dysfunction than Lewy bodies themselves.

In PDD, cortical Lewy pathology is typically more extensive than in PD without dementia. Limbic structures, cingulate cortex, temporal association cortex, parietal cortex, and frontal cortex may be involved. Neuronal loss and gliosis occur in affected regions, although cognitive impairment often reflects synaptic failure before frank neuronal loss.

Co-pathology is common. Amyloid plaques and tau neurofibrillary tangles may coexist, particularly in older patients. Cerebrovascular disease, TDP-43 pathology, hippocampal sclerosis, and age-related tau astrogliopathy may further modify clinical expression. This explains why two patients with similar motor PD duration can have dramatically different cognitive trajectories.

Table 7. Histopathological contributors to PDD

Pathology	Typical substrate	Clinical relevance
Cortical Lewy bodies and Lewy neurites	Misfolded α-synuclein	Core substrate of PDD
Limbic Lewy pathology	Amygdala, cingulate, hippocampal regions	Hallucinations, mood, memory, fluctuations
Cholinergic neuronal loss	Nucleus Basalis of Meynert	Attention, hallucinations, treatment response
Alzheimer-type pathology	Amyloid plaques and tau tangles	Faster decline, amnestic phenotype
Vascular pathology	Lacunes, infarcts, small vessel disease	Stepwise decline, gait worsening, reduced reserve
Synaptic degeneration	Cortical and subcortical networks	May correlate strongly with cognition
Neuroinflammation	Microglial activation	Potential amplifier of neurodegeneration

Management

1 General principles

The first step is to identify reversible contributors. Infection, dehydration, constipation, urinary retention, sleep deprivation, pain, medication toxicity, orthostatic hypotension, sensory impairment, and depression can all worsen cognition. Treating these contributors may improve function even when underlying dementia remains.

Medication review is central. Anticholinergics should generally be discontinued. Dopamine agonists, amantadine, monoamine oxidase-B inhibitors, catechol-O-methyltransferase inhibitors, sedatives, and opioids should be reviewed carefully. In patients with hallucinations or confusion, simplification often proceeds from anticholinergics and sedatives first, then amantadine, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and finally levodopa adjustments if necessary. Levodopa is usually preserved as the most effective and often best-tolerated motor therapy.

2 Cognitive pharmacotherapy

Rivastigmine has the strongest evidence and is approved for PDD in many jurisdictions. It improves global cognition, attention, executive symptoms, and neuropsychiatric symptoms modestly in some patients. Gastrointestinal adverse effects, tremor worsening, bradycardia, syncope, weight loss, and sleep disturbance require monitoring. Transdermal rivastigmine may improve tolerability.

Donepezil and galantamine have less robust evidence but may be considered when rivastigmine is not tolerated. Memantine has mixed evidence; it may provide modest global or behavioural benefit in selected patients but is not consistently effective for cognition.

Table 8. Pharmacologic treatment comparison in PDD

Treatment	Main indication	Evidence strength	Advantages	Limitations
Rivastigmine oral/transdermal	Cognitive symptoms in PDD	Strongest among cognitive agents	Approved; may help attention and hallucinations	GI effects, tremor, bradycardia, weight loss
Donepezil	Cognitive symptoms	Moderate/limited	Once daily; often tolerated	Less definitive PDD evidence
Galantamine	Cognitive symptoms	Limited	Cholinergic mechanism	Less studied in PDD
Memantine	Global/behavioural symptoms	Mixed	Generally tolerated	Modest and inconsistent cognitive benefit
Pimavanserin	Parkinson disease psychosis	Evidence for psychosis, not cognition	Less dopamine blockade	QT prolongation, cost/access
Quetiapine	Psychosis/agitation	Commonly used; limited trial evidence	Low motor worsening risk	Sedation, orthostasis, metabolic effects
Clozapine	Refractory psychosis	Strong efficacy for PD psychosis	Effective with minimal motor worsening	Agranulocytosis monitoring burden
SSRIs/SNRIs	Depression/anxiety	Symptom-based	Treats comorbid mood	Hyponatremia, falls, REM sleep effects
Melatonin/ clonazepam	REM sleep behaviour disorder	Symptom-based	Reduces dream enactment	Clonazepam worsens cognition/falls

3 Management of psychosis

Psychosis management begins with determining whether symptoms are distressing or dangerous. Benign hallucinations with preserved insight may not require antipsychotic therapy. When treatment is necessary, clinicians should first treat triggers and reduce offending medications. Pimavanserin is used for Parkinson disease psychosis in some regions and has the advantage of avoiding dopamine receptor blockade. Quetiapine is widely used because it is practical and usually has limited motor worsening, although controlled evidence is weaker. Clozapine is the most effective antipsychotic for PD psychosis but requires blood monitoring.

Typical antipsychotics and potent dopamine-blocking atypical antipsychotics such as risperidone and olanzapine should generally be avoided because they can worsen Parkinsonism and precipitate severe sensitivity reactions.

4 Motor management

Motor treatment in PDD requires conservative optimization. The goal is not maximal motor control at all costs, but the best balance between mobility, cognition, psychosis, orthostasis, dyskinesia, and caregiver feasibility. Levodopa remains the cornerstone. Dopamine agonists are often poorly tolerated in older cognitively impaired patients because they increase hallucinations, sleep attacks, edema, orthostasis, and impulse-control disorders.

Deep brain stimulation is generally not appropriate for patients with dementia. Cognitive impairment is a major contraindication because DBS may worsen cognition and does not treat axial, cognitive, or neuropsychiatric progression.

5 Non-pharmacologic management

Non-pharmacologic interventions are essential. These include structured routines, environmental cueing, medication dispensing systems, caregiver education, exercise adapted to fall risk, occupational therapy, physical therapy, speech-language therapy, swallowing evaluation, nutrition support, driving assessment, home safety assessment, and legal/financial planning.

Cognitive rehabilitation should be practical rather than restorative. Patients benefit from external memory aids, simplified choices, visual contrast enhancement, lighting optimization, reduction of clutter, sleep regularity, and caregiver-mediated routines. Exercise may support mobility, mood, sleep, and general health, although it is not a proven disease-modifying therapy for PDD.

6 Clinical management algorithm

Clinical problem	First step	Second step	Escalation
New cognitive decline	Exclude delirium, medication toxicity, metabolic causes	Cognitive testing and MRI	Biomarkers/neuropsychology if atypical
Hallucinations	Assess distress and insight; treat triggers	Reduce anticholinergics/dopamine agonists/amantadine	Pimavanserin, quetiapine, or clozapine
Cognitive symptoms	Start rivastigmine if appropriate	Switch formulation or alternative ChEI if intolerant	Consider memantine selectively
Falls	Review orthostasis, sedatives, vision, gait	PT, home safety, assistive devices	Specialist falls clinic
Orthostatic hypotension	Hydration, salt, compression, medication review	Midodrine/droxidopa/fludrocortisone when appropriate	Autonomic specialist
REM sleep behaviour disorder	Safety measures, remove hazards	Melatonin	Clonazepam cautiously
Depression/anxiety	Confirm syndrome, psychotherapy/support	SSRI/SNRI cautiously	Psychiatry referral
Caregiver strain	Education, respite, social work	Community resources	Long-term care planning

Prognosis

PDD is associated with worse prognosis than PD without dementia. It predicts accelerated functional decline, falls, psychosis, hospitalization, institutionalization, aspiration risk, frailty, and mortality. Prognosis varies widely according to age, comorbidity, motor severity, dysphagia, psychosis, autonomic dysfunction, caregiver support, and co-pathology.

The development of dementia often marks a transition in care goals. Medication regimens should be simplified, safety prioritized, and advance care planning revisited. Driving, financial capacity, medication management, firearm or hazard access, cooking safety, wandering risk, swallowing, nutrition, and caregiver sustainability should be assessed proactively.

Patients with prominent hallucinations, fluctuations, orthostatic hypotension, dysphagia, recurrent falls, or mixed Alzheimer pathology often progress faster. GBA mutation carriers may also show more rapid cognitive decline. Conversely, patients with slower dysexecutive progression, strong caregiver support, and fewer systemic complications may remain at home longer.

Future Directions

The future of PDD research is moving from syndromic diagnosis toward biological classification. α-Synuclein seed amplification assays may allow identification of synuclein biology during life and may help stratify patients for synuclein-targeted therapies. However, clinical implementation requires standardization, longitudinal validation, and interpretation alongside amyloid, tau, neurofilament light, inflammatory, lysosomal, and imaging biomarkers.

Disease-modifying strategies include anti-α-synuclein immunotherapy, small molecules reducing aggregation, enhancement of autophagy-lysosomal pathways, glucocerebrosidase-targeted therapy, mitochondrial support, anti-inflammatory approaches, and neurotrophic strategies. Prior trials in PD have faced challenges related to late intervention, heterogeneous biology, insensitive outcomes, and inadequate target engagement. Future PDD trials will likely require biomarker enrichment, earlier disease stages, digital cognitive endpoints, and stratification by co-pathology.

Precision medicine will be especially important. A patient with GBA-associated synucleinopathy, hallucinations, and positive α-synuclein SAA may require different intervention than a patient with PD, severe amyloid/tau positivity, and amnestic decline. The field is likely to move toward integrated Lewy body dementia frameworks rather than rigid separation of PDD and DLB.

Digital biomarkers may improve monitoring through passive gait analysis, speech metrics, sleep tracking, medication adherence data, and cognitive fluctuation detection. Ethical issues will become increasingly important, including disclosure of biomarker status, driving safety, autonomy, caregiver burden, and equitable access to advanced diagnostics and therapies.

Conclusion

Parkinson's disease dementia is a complex, heterogeneous, and clinically consequential disorder arising from diffuse synucleinopathy and interacting cholinergic, dopaminergic, Alzheimer-type, vascular, inflammatory, genetic, and network-level mechanisms. Its diagnosis requires careful temporal assessment, cognitive and functional characterization, exclusion of reversible causes, and differentiation from DLB, Alzheimer's disease, vascular cognitive impairment, medication effects, and delirium. Rivastigmine remains the best-supported symptomatic treatment, but optimal care is broader than pharmacotherapy and requires individualized medication rationalization, psychosis management, rehabilitation, caregiver support, and anticipatory planning. Future progress depends on biological staging, validated biomarkers, synuclein-targeted therapies, and precision approaches that recognize the heterogeneity of Lewy body dementias.

References

Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., & Kragh-Sørensen, P. (2003). Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Archives of Neurology, 60(3), 387–392.

Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021). Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 7, 47.

Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., Ffytche, D. H., Weintraub, D., & Ballard, C. (2017). Cognitive decline in Parkinson disease. Nature Reviews Neurology, 13(4), 217–231.

Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. JAMA, 323(6), 548–560.

Barker, R. A., Williams-Gray, C. H., & Yarnall, A. J. (2020). Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology, 46(1), 6–19.

Bohnen, N. I., & Albin, R. L. (2011). The cholinergic system and Parkinson disease. Behavioural Brain Research, 221(2), 564–573.

Bohnen, N. I., Müller, M. L. T. M., Kotagal, V., Koeppe, R. A., Kilbourn, M. R., Albin, R. L., & Frey, K. A. (2015). Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. Journal of Cerebral Blood Flow & Metabolism, 32(8), 1609–1617.

Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197–211.

Buter, T. C., van den Hout, A., Matthews, F. E., Larsen, J. P., Brayne, C., & Aarsland, D. (2008). Dementia and survival in Parkinson disease: A 12-year population study. Neurology, 70(13), 1017–1022.

Caviness, J. N., Driver-Dunckley, E., Connor, D. J., Sabbagh, M. N., Hentz, J. G., Noble, B., Evidente, V. G. H., Shill, H. A., & Adler, C. H. (2007). Defining mild cognitive impairment in Parkinson's disease. Movement Disorders, 22(9), 1272–1277.

Compta, Y., Parkkinen, L., O'Sullivan, S. S., Vandrovcova, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., Lees, A. J., & Revesz, T. (2011). Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: Which is more important? Brain, 134(5), 1493–1505.

Dickson, D. W. (2018). Neuropathology of Parkinson disease. Parkinsonism & Related Disorders, 46, S30–S33.

Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G. A., Dickson, D., Duyckaerts, C., Cummings, J., Gauthier, S., Korczyn, A., Lees, A., Levy, R., Litvan, I., Mizuno, Y., McKeith, I. G., Olanow, C. W., Poewe, W., Sampaio, C., … Emre, M. (2007). Diagnostic procedures for Parkinson's disease dementia: Recommendations from the Movement Disorder Society Task Force. Movement Disorders, 22(16), 2314–2324.

Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., Poewe, W., Robillard, A., Rosa, M. M., Wolters, E., Quarg, P., Tekin, S., Lane, R., & Rivastigmine PDD Study Group. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351(24), 2509–2518.

Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., Goldman, J., Goetz, C., Korczyn, A., Lees, A., Levy, R., Litvan, I., McKeith, I., Olanow, W., Poewe, W., … Dubois, B. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22(12), 1689–1707.

Fénelon, G., Soulas, T., Zenasni, F., & Cleret de Langavant, L. (2010). The changing face of Parkinson's disease-associated psychosis: A cross-sectional study based on the new NINDS-NIMH criteria. Movement Disorders, 25(6), 755–759.

Ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017). The psychosis spectrum in Parkinson disease. Nature Reviews Neurology, 13(2), 81–95.

Fuchs, J., Nilsson, C., Kachergus, J., Munz, M., Larsson, E. M., Schüle, B., Langston, J. W., Middleton, F. A., Ross, O. A., Hulihan, M., Gasser, T., & Farrer, M. J. (2007). Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology, 68(12), 916–922.

Gan-Or, Z., Liong, C., & Alcalay, R. N. (2018). GBA-associated Parkinson's disease and other synucleinopathies. Current Neurology and Neuroscience Reports, 18(8), 44.

Goldman, J. G., & Holden, S. (2014). Treatment of psychosis and dementia in Parkinson's disease. Current Treatment Options in Neurology, 16(3), 281.

Goldman, J. G., Vernaleo, B. A., Camicioli, R., Dahodwala, N., Dobkin, R. D., Ellis, T., Galvin, J. E., Marras, C., Edwards, J., Fields, J., Golden, R., Karlawish, J., Levin, B., Shulman, L., Smith, G., Tangney, C., Thomas, C. A., Tröster, A. I., Uc, E. Y., & Coyan, N. (2018). Cognitive impairment in Parkinson's disease: A report from a multidisciplinary symposium on unmet needs and future directions. NPJ Parkinson's Disease, 4, 19.

Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders, 29(5), 634–650.

Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008). The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Movement Disorders, 23(6), 837–844.

Höglinger, G. U., Adler, C. H., Berg, D., Klein, C., Outeiro, T. F., Poewe, W., Postuma, R., Stoessl, A. J., Lang, A. E., & MDS Task Force. (2024). A biological classification of Parkinson's disease: The SynNeurGe research diagnostic criteria. The Lancet Neurology, 23(2), 191–204.

Irwin, D. J., Lee, V. M. Y., & Trojanowski, J. Q. (2013). Parkinson's disease dementia: Convergence of α-synuclein, tau and amyloid-β pathologies. Nature Reviews Neuroscience, 14(9), 626–636.

Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896–912.

Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. The Lancet Neurology, 9(12), 1200–1213.

Kempster, P. A., O'Sullivan, S. S., Holton, J. L., Revesz, T., & Lees, A. J. (2010). Relationships between age and late progression of Parkinson's disease: A clinico-pathological study. Brain, 133(6), 1755–1762.

Kramer, M. L., & Schulz-Schaeffer, W. J. (2007). Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. Journal of Neuroscience, 27(6), 1405–1410.

Lawson, R. A., Yarnall, A. J., Duncan, G. W., Breen, D. P., Khoo, T. K., Williams-Gray, C. H., Barker, R. A., Collerton, D., Taylor, J. P., Burn, D. J., & ICICLE-PD Study Group. (2016). Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism & Related Disorders, 27, 47–53.

Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams-Gray, C. H., Aarsland, D., Kulisevsky, J., Rodriguez-Oroz, M. C., Burn, D. J., Barker, R. A., & Emre, M. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders, 27(3), 349–356.

Liu, G., Boot, B., Locascio, J. J., Jansen, I. E., Winder-Rhodes, S., Eberly, S., Elbaz, A., Brice, A., Ravina, B., van Hilten, J. J., Cormier-Dequaire, F., Corvol, J. C., Barker, R. A., Heutink, P., Marinus, J., Williams-Gray, C. H., Scherzer, C. R., & International Genetics of Parkinson Disease Progression Consortium. (2016). Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology, 80(5), 674–685.

Marras, C., Chaudhuri, K. R., Titova, N., Mestre, T. A., & Group, P. (2020). Therapy of Parkinson's disease subtypes. Neurotherapeutics, 17(4), 1366–1377.

McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J. P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., Bayston, A., Beach, T. G., Blanc, F., Bohnen, N., Bonanni, L., Bras, J., Brundin, P., Burn, D., Chen-Plotkin, A., … Kosaka, K. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report. Neurology, 89(1), 88–100.

Mollenhauer, B., Dakna, M., Kruse, N., Galasko, D., Foroud, T., Zetterberg, H., Schade, S., Gera, R. G., Wang, W., & Zhang, J. (2023). Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression. Movement Disorders, 38(3), 441–451.

Muslimović, D., Post, B., Speelman, J. D., & Schmand, B. (2005). Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology, 65(8), 1239–1245.

Outeiro, T. F., Koss, D. J., Erskine, D., Walker, L., Kurzawa-Akanbi, M., Burn, D., Donaghy, P., Morris, C., Taylor, J. P., Thomas, A., Attems, J., & McKeith, I. (2019). Dementia with Lewy bodies: An update and outlook. Molecular Neurodegeneration, 14, 5.

Pagano, G., Niccolini, F., & Politis, M. (2016). Imaging in Parkinson's disease. Clinical Medicine, 16(4), 371–375.

Pagonabarraga, J., & Kulisevsky, J. (2012). Cognitive impairment and dementia in Parkinson's disease. Neurobiology of Disease, 46(3), 590–596.

Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A. E., & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591–1601.

Postuma, R. B., Iranzo, A., Hu, M., Högl, B., Boeve, B. F., Manni, R., Oertel, W. H., Arnulf, I., Ferini-Strambi, L., Puligheddu, M., Antelmi, E., Cochen De Cock, V., Arnaldi, D., Mollenhauer, B., Videnovic, A., Sonka, K., Jung, K. Y., Kunz, D., Dauvilliers, Y., … Pelletier, A. (2019). Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study. Brain, 142(3), 744–759.

Rongve, A., Aarsland, D., & Ballard, C. (2016). Management of dementia with Lewy bodies and Parkinson's disease dementia. Drugs & Aging, 33(11), 803–813.

Schneider, J. S., Aras, R., Williams, C. K., Koprich, J. B., Brotchie, J. M., & Singh, V. (2019). GM1 ganglioside modifies α-synuclein toxicity and is neuroprotective in a rat α-synuclein model of Parkinson's disease. Scientific Reports, 9, 8362.

Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group. (2019). Update on treatments for nonmotor symptoms of Parkinson's disease: An evidence-based medicine review. Movement Disorders, 34(2), 180–198.

Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C. M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H. C., … Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine, 361(17), 1651–1661.

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., … Gwinn-Hardy, K. (2003). α-Synuclein locus triplication causes Parkinson's disease. Science, 302(5646), 841.

Smith, G. E., Housholder, D. B., Wyman-Chick, K. A., Geda, Y. E., Fields, J. A., Jacobson, D. J., & Adler, C. H. (2021). Parkinson disease mild cognitive impairment and dementia: Cognitive profiles and clinical outcomes. Movement Disorders Clinical Practice, 8(1), 67–75.

Stinton, C., McKeith, I., Taylor, J. P., Lafortune, L., Mioshi, E., Mak, E., Cambridge, V., Mason, J., Thomas, A., & O'Brien, J. T. (2015). Pharmacological management of Lewy body dementia: A systematic review and meta-analysis. American Journal of Psychiatry, 172(8), 731–742.

Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., Kramer, P., Woltjer, R., Trojanowski, J. Q., Weintraub, D., Chen-Plotkin, A., Irwin, D. J., Rick, J., Schellenberg, G. D., Watson, G. S., … Zabetian, C. P. (2013). APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurology, 70(2), 223–228.

Weil, R. S., Costantini, A. A., & Schrag, A. E. (2018). Mild cognitive impairment in Parkinson's disease: What is it? Current Neurology and Neuroscience Reports, 18(4), 17.

Weintraub, D., Chiang, C., Kim, H. M., Wilkinson, J., Marras, C., Stanislawski, B., Mamikonyan, E., Kales, H. C., & Parkinson Study Group. (2016). Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurology, 73(5), 535–541.

Weintraub, D., & Mamikonyan, E. (2019). The neuropsychiatry of Parkinson disease: A perfect storm. American Journal of Geriatric Psychiatry, 27(9), 998–1018.

Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., & Barker, R. A. (2009). The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain, 132(11), 2958–2969.

Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., Nombela, C., Winder-Rhodes, S., Evans, J. R., Rowe, J. B., Mollenhauer, B., Kruse, N., Hudson, G., Chinnery, P. F., O'Brien, J. T., Robbins, T. W., Wesnes, K., Brooks, D. J., Barker, R. A., … Burn, D. J. (2014). Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD study. Neurology, 82(4), 308–316.

Yarnall, A. J., Lawson, R. A., Duncan, G. W., Breen, D. P., Khoo, T. K., Brooks, D., Barker, R. A., Burn, D. J., & ICICLE-PD Study Group. (2016). Cognitive decline in Parkinson disease. Nature Reviews Neurology, 13(4), 217–231.

Zhang, J., Mattison, H. A., Liu, C., Ginghina, C., Auinger, P., McDermott, M. P., Kang, U. J., Cain, K. C., Shi, M., Bollen, A. W., & Siderowf, A. (2013). Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathologica, 126(5), 671–682.